POSITION
Co-investor
BOARD
None
A Fund III clinical-stage biotechnology portfolio company with operations in Montreal and Boston. Engene is pioneering novel non-viral genetic medicines based on its proprietary Dually Derivatived Chitosan (DDX) mucosal-barrier penetrating gene delivery platform. enGene’s lead program, EG-70 (detalimogene voraplasmid), is in an ongoing pivotal clinical trial in patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ.
In November 2023, following the close of a business combination with a special purpose acquisition company and an associated private financing totalling approximately $138 million USD, enGene became a publicly traded company. CTI LSF Fund III participated in the private financing round alongside new and existing investors including Forbion Ventures III, BVF Partners, Omega Funds, Cowen Healthcare Investments, Vivo Capital and Northleaf Capital Partners. enGene shares are currently trading on the Nasdaq market under the ticker symbol ENGN.